KPTI Quote, Financials, Valuation and Earnings

Pacira BioSciences has a net margin of -100.78% compared to Karyopharm Therapeutics's net margin of 8.57%. Karyopharm Therapeutics's return on equity of -- beat Pacira BioSciences's return on equity of -11.94%.

Karyopharm Therapeutics has a consensus price target of $48.64, signalling upside risk potential of 1055.41%. On the other hand Pacira BioSciences has an analysts' consensus of $36.00 which suggests that it could grow by 44.17%. Given that Karyopharm Therapeutics has higher upside potential than Pacira BioSciences, analysts believe Karyopharm Therapeutics is more attractive than Pacira BioSciences.

Karyopharm Therapeutics has a beta of 0.584, which suggesting that the stock is 41.592% less volatile than S&P 500. In comparison Pacira BioSciences has a beta of 0.706, suggesting its less volatile than the S&P 500 by 29.437%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacira BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Pacira BioSciences pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30.5M, which are smaller than Pacira BioSciences quarterly revenues of $187.3M. Karyopharm Therapeutics's net income of -$30.8M is lower than Pacira BioSciences's net income of $16M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Pacira BioSciences's PE ratio is 11.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.25x versus 1.74x for Pacira BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -100.78% compared to Karyopharm Therapeutics's net margin of 24.22%. Karyopharm Therapeutics's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Karyopharm Therapeutics has a consensus price target of $48.64, signalling upside risk potential of 1055.41%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $893.09 which suggests that it could grow by 56.39%. Given that Karyopharm Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than Regeneron Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.584, which suggesting that the stock is 41.592% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Karyopharm Therapeutics's net income of -$30.8M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.25x versus 4.63x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -100.78% compared to Karyopharm Therapeutics's net margin of 24.16%. Karyopharm Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

Karyopharm Therapeutics has a consensus price target of $48.64, signalling upside risk potential of 1055.41%. On the other hand Sarepta Therapeutics has an analysts' consensus of $155.00 which suggests that it could grow by 183.73%. Given that Karyopharm Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Karyopharm Therapeutics is more attractive than Sarepta Therapeutics.

Karyopharm Therapeutics has a beta of 0.584, which suggesting that the stock is 41.592% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30.5M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Karyopharm Therapeutics's net income of -$30.8M is lower than Sarepta Therapeutics's net income of $159M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 23.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.25x versus 3.20x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -100.78% compared to Karyopharm Therapeutics's net margin of 31.35%. Karyopharm Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

Karyopharm Therapeutics has a consensus price target of $48.64, signalling upside risk potential of 1055.41%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.01 which suggests that it could grow by 0.44%. Given that Karyopharm Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than Vertex Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.584, which suggesting that the stock is 41.592% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30.5M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Karyopharm Therapeutics's net income of -$30.8M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.25x versus 11.67x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.